Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

19.90 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutic Com

< Previous 1 2 3 4 5 6 7 8 9 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Where Sage Therapeutics Stands With Analysts
Via Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. 
Via InvestorPlace
Sage Therapeutics to Present at Upcoming September Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Is Sage Therapeutics a Contrarian Buy?
A regulatory setback weighed heavily on the drugmaker's shares Monday. 
Via The Motley Fool
Why Sage Therapeutics Stock Is Crashing Today
Sage's regulatory win wasn't enough to offset an even bigger regulatory loss. 
Via The Motley Fool
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Via ACCESSWIRE
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
The company is now focusing on its launch in postpartum depression. 
Via Investor's Business Daily
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
From Sage Therapeutics, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Blink, Lovesac, and Sage and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Very Oversold Pharma Stocks to Buy Right Now
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy. 
Via InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
The pharmaceutical company's growth prospects have taken a big hit. 
Via The Motley Fool
SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Why Shares of Sage Therapeutics Slumped This Week
The company got bad news from the FDA and saw increased losses. 
Via The Motley Fool
Exposures Product Safety
Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
2 Beaten-Down Stocks That Still Aren't Worth Buying
These companies aren't bargains at all. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Market Volatility Falls Sharply, S&P 500 Snaps 4-Session Losing Streak
The S&P 500 settled higher on Monday, snapping a four-session losing streak. U.S. stocks have notched sharp gains this year, with the benchmark S&P 500 adding around 17.7% in 2023. As far as the... 
Via Benzinga
Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P... 
Via Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Dow Rises Over 300 Points To Start The Week
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses. 
Via Talk Markets
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
Crude Oil Down Over 1%; Henry Schein Earnings Top Views
U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday. The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 7, 2023
Via Benzinga
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
Why Sage Therapeutics Shares Are Sinking Monday
Sage Therapeutics Inc (NASDAQ: SAGE) shares are trading lower Monday after the company announced the FDA issued a Complete Response Letter (CRL) for one of the company's 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.